SynthesisJournal of gastrointestinal cancer2026
Perioperative Chemoimmunotherapy vs. Chemotherapy Alone for Gastroesophageal Cancer: A Systematic Review and Meta-Analysis.
Synthesis in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo systematically evaluate the efficacy and safety of adding immune checkpoint inhibitors (ICIs) to perioperative or neoadjuvant chemotherapy versus chemotherapy alone in resectable gastric and gastroesophageal junction (GEJ) adenocarcinoma.
methodsPubMed, Embase, and Cochrane CENTRAL were searched through July 31, 2025. Outcomes included event-free survival (EFS), pathologic complete response (pCR), overall survival (OS), disease-free survival (DFS), major pathologic response (MPR), R0 resection rate, and safety. Hazard ratios (HRs) and risk ratios (RRs) were pooled with random-effects models.
resultsTwenty studies (6 randomized controlled trials and 14 non-randomized comparative studies; 5,317 patients) were analyzed. Immunochemotherapy improved EFS (HR, 0.76; 95% CI, 0.66–0.87) and DFS (HR, 0.69; 95% CI, 0.60–0.78), with a nonsignificant trend for OS (HR, 0.81; 95% CI, 0.64–1.02). No significant effect modification by treatment timing (neoadjuvant-only vs. perioperative) was observed. Pathologic outcomes favored immunochemotherapy: pCR (RR, 2.93; 95% CI, 2.39–3.59) and MPR (RR, 1.59; 95% CI, 1.34–1.90). R0 resection rates were marginally higher (RR, 1.02; 95% CI, 1.00–1.03). Rates of grade ≥ 3 treatment-related adverse events (RR, 1.07; 95% CI, 0.97–1.17) and severe postoperative complications (RR, 1.00; 95% CI, 0.65–1.53) were comparable between groups. The pCR benefit was most pronounced in microsatellite instability–high tumors (RR, 5.18; 95% CI, 2.43–11.05).
conclusionAdding ICIs to perioperative or neoadjuvant chemotherapy for resectable gastric and GEJ adenocarcinoma improves EFS, DFS, and pathological responses, without increasing severe toxicity or postoperative morbidity. R0 resection differences appeared clinically limited. MSI-H status emerged as a potential predictor of benefit.
Indexed as
Identifiers
41670791What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.